Karyopharm Therapeutics (KPTI) Competitors $0.62 -0.04 (-6.32%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$0.66 +0.04 (+6.09%) As of 01/31/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends KPTI vs. TNGX, CRVS, NMRA, BTMD, TSHA, ALMS, VYGR, ENGN, TRVI, and SOPHShould you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include Tango Therapeutics (TNGX), Corvus Pharmaceuticals (CRVS), Neumora Therapeutics (NMRA), biote (BTMD), Taysha Gene Therapies (TSHA), Alumis (ALMS), Voyager Therapeutics (VYGR), enGene (ENGN), Trevi Therapeutics (TRVI), and SOPHiA GENETICS (SOPH). These companies are all part of the "pharmaceutical products" industry. Karyopharm Therapeutics vs. Tango Therapeutics Corvus Pharmaceuticals Neumora Therapeutics biote Taysha Gene Therapies Alumis Voyager Therapeutics enGene Trevi Therapeutics SOPHiA GENETICS Tango Therapeutics (NASDAQ:TNGX) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, community ranking and media sentiment. Which has preferable valuation & earnings, TNGX or KPTI? Tango Therapeutics has higher earnings, but lower revenue than Karyopharm Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTango Therapeutics$36.53M8.76-$101.74M-$1.18-2.53Karyopharm Therapeutics$146.03M0.54-$143.10M-$1.14-0.55 Do institutionals and insiders hold more shares of TNGX or KPTI? 79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 6.3% of Tango Therapeutics shares are owned by company insiders. Comparatively, 2.8% of Karyopharm Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts rate TNGX or KPTI? Tango Therapeutics currently has a consensus target price of $13.14, indicating a potential upside of 341.04%. Karyopharm Therapeutics has a consensus target price of $5.00, indicating a potential upside of 703.73%. Given Karyopharm Therapeutics' higher probable upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Tango Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tango Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Karyopharm Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is TNGX or KPTI more profitable? Karyopharm Therapeutics has a net margin of -58.93% compared to Tango Therapeutics' net margin of -284.42%. Karyopharm Therapeutics' return on equity of 0.00% beat Tango Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tango Therapeutics-284.42% -49.64% -32.00% Karyopharm Therapeutics -58.93%N/A -41.25% Does the media favor TNGX or KPTI? In the previous week, Karyopharm Therapeutics had 1 more articles in the media than Tango Therapeutics. MarketBeat recorded 4 mentions for Karyopharm Therapeutics and 3 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.07 beat Karyopharm Therapeutics' score of 0.84 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Karyopharm Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer TNGX or KPTI? Karyopharm Therapeutics received 508 more outperform votes than Tango Therapeutics when rated by MarketBeat users. However, 73.68% of users gave Tango Therapeutics an outperform vote while only 72.24% of users gave Karyopharm Therapeutics an outperform vote. CompanyUnderperformOutperformTango TherapeuticsOutperform Votes2873.68% Underperform Votes1026.32% Karyopharm TherapeuticsOutperform Votes53672.24% Underperform Votes20627.76% Which has more risk & volatility, TNGX or KPTI? Tango Therapeutics has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.07, meaning that its stock price is 93% less volatile than the S&P 500. SummaryTango Therapeutics beats Karyopharm Therapeutics on 9 of the 16 factors compared between the two stocks. Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPTI vs. The Competition Export to ExcelMetricKaryopharm TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$83.34M$6.91B$5.59B$9.12BDividend YieldN/A2.90%5.31%3.99%P/E RatioN/A4.3057.1113.81Price / Sales0.54321.061,261.0581.64Price / CashN/A73.5045.9637.70Price / Book-0.525.275.124.71Net Income-$143.10M$136.98M$111.17M$224.24M7 Day Performance-11.12%-0.59%2.37%-0.17%1 Month Performance-8.01%0.18%3.19%0.60%1 Year Performance-30.90%7.68%24.69%20.43% Karyopharm Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPTIKaryopharm Therapeutics4.0016 of 5 stars$0.62-6.3%$5.00+703.7%-17.1%$83.34M$146.03M-0.55380TNGXTango Therapeutics3.1764 of 5 stars$3.06+0.5%$13.14+330.2%-74.6%$328.17M$36.53M-2.5990News CoveragePositive NewsCRVSCorvus Pharmaceuticals2.4524 of 5 stars$5.04-4.6%$12.38+145.6%+168.0%$323.23MN/A-5.4130Short Interest ↑Positive NewsNMRANeumora Therapeutics4.222 of 5 stars$1.99-6.4%$16.50+731.2%-87.0%$320.70MN/A-1.06108Short Interest ↓BTMDbiote2.9487 of 5 stars$5.72+3.8%$9.14+59.7%+34.3%$310.83M$185.36M22.00194Short Interest ↑News CoverageGap DownTSHATaysha Gene Therapies4.0157 of 5 stars$1.53+0.3%$6.63+334.4%-1.3%$310.48M$15.45M2.40180Positive NewsALMSAlumisN/A$6.56-1.9%$26.83+309.3%N/A$310.00MN/A0.00N/AAnalyst ForecastNews CoverageVYGRVoyager Therapeutics4.7456 of 5 stars$5.62flat$15.97+184.1%-25.0%$306.47M$250.01M7.90100ENGNenGene3.052 of 5 stars$6.90-3.7%$29.78+331.9%-14.5%$304.90MN/A-11.8931Short Interest ↓News CoverageTRVITrevi Therapeutics2.5838 of 5 stars$3.87-1.2%$9.31+140.9%+177.5%$296.26MN/A-8.7620Short Interest ↓News CoverageSOPHSOPHiA GENETICS2.8195 of 5 stars$4.42+5.2%$7.40+67.4%-23.7%$288.96M$64.49M-4.06520Short Interest ↓Gap DownHigh Trading Volume Related Companies and Tools Related Companies Tango Therapeutics Competitors Corvus Pharmaceuticals Competitors Neumora Therapeutics Competitors biote Competitors Taysha Gene Therapies Competitors Alumis Competitors Voyager Therapeutics Competitors enGene Competitors Trevi Therapeutics Competitors SOPHiA GENETICS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KPTI) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
